US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.33

-1.0900-8.78%

Post-market: 11.400.0700+0.62%19:30 EDT

Volume:299.63K

Turnover:3.40M

Market Cap:3.84B

PE:-536.97

High:11.39

Open:11.34

Low:11.19

Close:12.42

52wk High:12.60

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:2.20

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0211

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.88

PE(LYR):-536.97

Loading ...

Overview Company News Filings

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

Telix to Release Escrowed Shares from Lightpoint Acquisition

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

ASX Growth Leaders With High Insider Ownership April 2026

Simply Wall St.

How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

MT Newswires Live

Telix Pharmaceuticals Issues New Tranche of Unquoted Convertible Notes

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch

Simply Wall St.

Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows

MT Newswires Live

Telix Sets Hybrid 2026 AGM to Engage Global Investor Base

Telix raises US$600m via new convertible notes to refinance 2029 bonds

Telix Pharmaceuticals Says JPMorgan Increases Stake

MT Newswires Live

Canaccord Genuity Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Issues New Unquoted Share Rights Under Employee Incentive Scheme

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)

Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial

MT Newswires Live

Telix Pharmaceuticals Files Appendix 3B for Proposed Securities Issue

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

Top Premarket Decliners

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/TLX/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.33,"timestamp":1787342400000,"preClose":12.42,"halted":0,"volume":299625,"hourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"delay":0,"changeRate":-0.08776167471819644,"floatShares":272000000,"shares":339000000,"eps":-0.0211,"marketStatus":"Market Closed","change":-1.09,"latestTime":"08-21 16:00:00 EDT","open":11.34,"high":11.39,"low":11.19,"amount":3395453.5710000005,"amplitude":0.016103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":12.42,"preHourTrading":{"tag":"盘前","latestPrice":11.3,"preClose":12.42,"latestTime":"09:29 EDT","volume":9930,"amount":113052.21588,"timestamp":1787318999999,"change":-1.12,"changeRate":-0.090177,"amplitude":0.02818},"postHourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"volumeRatio":2.1988469508579978},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":2.1988469508579978,"shares":339000000,"dividePrice":0,"high":11.39,"amplitude":0.016103,"preClose":12.42,"low":11.19,"week52Low":6.28,"pbRate":"7.88","psRate":"4.31","week52High":12.5999,"institutionHeld":0,"latestPrice":11.33,"eps":-0.0211,"divideRate":0,"volume":299625,"delay":0,"ttmEps":-0.0211,"open":11.34,"prevYearClose":7.49,"prevWeekClose":11.82,"prevMonthClose":9.89,"prevQuarterClose":11.53,"fiveDayClose":11.82,"twentyDayClose":10.22,"sixtyDayClose":9.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-21","current":-536.966825,"percent":0.281179,"low":-584.49693,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"high":383.853933,"avg":21.978205,"sd":314.696392,"marketCap":3778875522.96},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96}],"updateTime":1787504745396},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631245605","title":"OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2631245605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631245605?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:00","pubTimestamp":1777496400,"startTime":"0","endTime":"0","summary":"TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.OPTIMAL-PSMA2 initial dosimetry dat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284336/0/en/OPTIMAL-PSMA-Trial-of-TLX597-Tx-Next-Generation-RLT-Presented-at-IPCS-2026-Highlighting-Therapeutic-Potential-in-Prostate-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK4141","BK4139","TLX","BK4543","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631676285","title":"Telix to Release Escrowed Shares from Lightpoint Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2631676285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631676285?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:08","pubTimestamp":1777450090,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceuticals has announced that 45,584 ordinary shares issued to Lightpoint M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-from-lightpoint-acquisition-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-from-lightpoint-acquisition-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630346067","title":"Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2630346067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630346067?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:27","pubTimestamp":1777332420,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April  28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3282155/0/en/Educational-Webinar-Unlocking-the-Potential-of-PSMA-Therapy-A-Next-Generation-Portfolio-Approach.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK4139","TLX","BK4141","BK4543","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331928","title":"ASX Growth Leaders With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331928?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:08","pubTimestamp":1777230494,"startTime":"0","endTime":"0","summary":"As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AV1.AU","BK7096","BK7036","FRS.AU","BK7110","BK7095","EIQ.AU","SKS.AU","BK7508","BK7506","IMA.AU","BK7067","AMI.AU","TLX.AU","BK7113","TOR.AU","XAO.AU","TTT.AU","BK7016","BK7104","TLX","REG.AU","MAU.AU","BK4139","XKO.AU","BK7023","AR1.AU","SPL.AU","BK7501","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629584720","title":"How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2629584720","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629584720?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:05","pubTimestamp":1777028712,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced several milestones, including the first patient dosed in the pivotal Phase 3 IPAX BrIGHT trial of TLX101-Tx for recurrent glioblastoma and the upcoming presentation of Phase 3 safety data for its prostate cancer therapy TLX591-Tx at the 2026 ASCO Annual Meeting.\nIn parallel, Regeneron Pharmaceuticals and Telix entered a broad collaboration pairing Regeneron’s antibody portfolio with Telix’s radiopharmaceutical platform, potentially expanding Telix’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629809008","title":"Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629809008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629809008?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:16","pubTimestamp":1776910582,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is \"substantially complete.\"After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX","BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629077453","title":"Telix Pharmaceuticals Issues New Tranche of Unquoted Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629077453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629077453?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:17","pubTimestamp":1776907056,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals Limited has notified the market of the issuance of an additional tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-issues-new-tranche-of-unquoted-convertible-notes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-issues-new-tranche-of-unquoted-convertible-notes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629636900","title":"ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629636900","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629636900?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:49","pubTimestamp":1776804540,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April  22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the Pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278510/0/en/ProstACT-Global-Phase-3-Part-1-Selected-as-Late-Breaking-Abstract-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4141","ASX","BK4526","BK4139","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629070229","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070229","media":"Simply Wall St.","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070229?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:10","pubTimestamp":1776737430,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh investor attention after Regeneron agreed to a US$40 million upfront payment to access its radiopharmaceutical platform, alongside Telix starting the pivotal Phase 3 IPAX BrIGHT trial in recurrent glioblastoma.\nSee our latest analysis for Telix Pharmaceuticals.\nAgainst this backdrop, Telix’s recent news is landing on a share price that has gained 15.76% over the past 30 days and 28.46% over 90 days, while the 1 year total shareholder return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703479","title":"Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703479","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629703479?lang=en_us&edition=fundamental","pubTime":"2026-04-21 09:55","pubTimestamp":1776736508,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  was the most shorted stock on the Australian Securities Exchange as of April 15 with 16.51% short positions, taking the place of Domino's Pizza Enterprises , according to data from the Australian Securities & Investments Commission.Domino's Pizza is now the second most shorted stock with 15.44% short positions, data showed.Telix Pharmaceuticals' shares fell 2% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1548497426.USD","LU1861219969.SGD","LU2360107325.USD","ON","LU0124384867.USD","BK4139","LU2357305700.SGD","BK7137","BK4141","BK4107","LU0724618433.USD","BK4588","LU1861215975.USD","BK4512","LU1978683503.SGD","LU1854103824.USD","DMP.AU","LU1861214812.USD","ASIC","BK4585","LU1861220033.SGD","LU1854104046.USD","BK7067","LU2298322129.HKD","LU0348723411.USD","TLX","BK4605","LU1720051017.SGD","LU1720051108.HKD","IE00BZ199S13.USD","IE00BD6J9T35.USD","IE00BFMHRM44.USD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629177476","title":"Telix Sets Hybrid 2026 AGM to Engage Global Investor Base","url":"https://stock-news.laohu8.com/highlight/detail?id=2629177476","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629177476?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:44","pubTimestamp":1776725084,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceuticals has scheduled its 2026 Annual General Meeting for May 21 in Melb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-sets-hybrid-2026-agm-to-engage-global-investor-base?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-sets-hybrid-2026-agm-to-engage-global-investor-base?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","AGM","BK4195","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628717538","title":"Telix raises US$600m via new convertible notes to refinance 2029 bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2628717538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628717538?lang=en_us&edition=fundamental","pubTime":"2026-04-20 15:19","pubTimestamp":1776669553,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has detailed the issuance of US$600 million in 1.5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-raises-us600m-via-new-convertible-notes-to-refinance-2029-bonds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-raises-us600m-via-new-convertible-notes-to-refinance-2029-bonds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628606227","title":"Telix Pharmaceuticals Says JPMorgan Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2628606227","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628606227?lang=en_us&edition=fundamental","pubTime":"2026-04-17 13:35","pubTimestamp":1776404146,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said JPMorgan Chase & Co. and its affiliates have increased their stake in the company on Tuesday to 11.5% or 39 million shares from 7.7% or 26.1 million shares, according to a Friday Australian bourse filing.The company's shares fell past 2% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","LU0345770993.USD","IE0034235303.USD","JPMO","LU2264538146.SGD","TLX","LU2213496289.HKD","LU2023250504.SGD","IE00BJTD4N35.SGD","LU0417517546.SGD","IE00BYXW3230.USD","LU2756315318.SGD","LU0265550359.USD","LU2430703251.USD","BK7067","IE00BWXC8680.SGD","LU0215105999.USD","LU0859254822.USD","LU1548497426.USD","LU1084165304.USD","IE00BDRTCR15.USD","JPO","LU0868494617.USD","LU0942090050.USD","LU1670628061.USD","LU1917777945.USD","BK4585","LU0964807845.USD","LU0211326839.USD","TLX.AU","LU2756315664.SGD","LU1116320901.HKD","LU2746668461.USD","LU0345769631.USD","LU2242649171.HKD","LU1720051017.SGD","LU2552382132.HKD","LU2023250843.SGD","LU0211328371.USD","LU0251132253.USD","LU1668664300.SGD","BK4550","LU2237443382.USD","LU0106261372.USD","BK4139","LU0310799852.SGD","LU1116320737.USD","LU0203345920.USD","LU0211327993.USD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628819240","title":"Canaccord Genuity Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628819240","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628819240?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:38","pubTimestamp":1776382695,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$30.00. Storey covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627073260","title":"Telix Issues New Unquoted Share Rights Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2627073260","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627073260?lang=en_us&edition=fundamental","pubTime":"2026-04-16 16:13","pubTimestamp":1776327200,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has notified the market of the issue of new unquoted share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-unquoted-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-unquoted-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627284519","title":"Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627284519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627284519?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:21","pubTimestamp":1776255689,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbCellera Biologics (ABCL), Telix Pharmaceuticals (T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abcellera-biologics-abcl-telix-pharmaceuticals-othertlppf-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abcellera-biologics-abcl-telix-pharmaceuticals-othertlppf-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0203345920.USD","IE000SO60NU8.SGD","IE00BLSP4452.SGD","XLV","LU1066051498.USD","BK4139","IE00B4R5TH58.HKD","TLX","LU2592432038.USD","LU1261432733.SGD","LU0426412945.USD","LU1244550221.USD","LU2129689514.USD","IE00BFXG1179.USD","SGXZ57979304.SGD","LU0432979614.USD","LU1057294990.SGD","LU1267930813.SGD","XBI","IE00B19Z3581.USD","BK4568","LU1718418525.SGD","LU0098860793.USD","LU2347655156.SGD","LU0029874061.USD","SG9999002224.SGD","LU0345769631.USD","LU1043141396.HKD","LU1935042991.SGD","IE00BFTCPJ56.SGD","LU2505996681.GBP","IE000BZT7R73.USD","IE00BJJMRZ35.SGD","LU1244550494.USD","BK4533","LU1221951046.USD","LU0882574055.USD","LU0889566641.SGD","ABCL","IE000F7OJYX1.SGD","JNJ","LU0234570918.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","HCSG","BK4559","LU1061106388.HKD","LU0683600562.USD","LU2471134952.CNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627400631","title":"Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400631","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627400631?lang=en_us&edition=fundamental","pubTime":"2026-04-15 17:30","pubTimestamp":1776245418,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Wednesday it dosed the initial patient in a Phase 3 clinical trial evaluating its radiopharmaceutical therapy for recurrent glioblastoma, a type of brain cancer.The gl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478475","title":"Telix Pharmaceuticals Files Appendix 3B for Proposed Securities Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478475?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:48","pubTimestamp":1776210514,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has lodged an Appendix 3B with the ASX outlining a proposed issue o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-files-appendix-3b-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-files-appendix-3b-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627203064","title":"Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627203064","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627203064?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:50","pubTimestamp":1776207000,"startTime":"0","endTime":"0","summary":"The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHTis assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy , compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, includingIPAX-1[3], which reported a median overall survival  of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis[4]. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of12.4 monthsfrom initiation of treatment and32.2 monthsfrom initial diagnosis[5]. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, fur","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-doses-first-patient-in-phase-3-ipax-bright-trial-of-tlx101-tx-for-recurrent-glioblastoma-302742412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK7039","BK4141","BK4543","BK4139","BK7067","SEC.AU","TLX.AU","XAO.AU","XKO.AU","XJO.AU","BK4526","BK7104","GBM.AU","TLX","ASX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445663","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445663","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445663?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:01","pubTimestamp":1776168074,"startTime":"0","endTime":"0","summary":"T1 Energy  shares were 5.7% lower in Tuesday's premarket activity after the company said it is proposing an underwritten public offering of $125 million in convertible senior notes due 2031.CarMax  shares were down 4.2% after the company reported lower fiscal Q4 adjusted earnings and net sales and operating revenue from a year earlier.Telix Pharmaceuticals  stock was 5.1% lower after the company said it commenced a $550 million offering of convertible notes due 2031.Wells Fargo  shares were down 2.4% after the Wall Street bank reported lower-than-expected Q1 revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2361045086.USD","LU0477156953.USD","LU1791807156.HKD","IE00B19Z3B42.SGD","LU0106831901.USD","LU0310800379.SGD","IE000M9KFDE8.USD","LU0640476718.USD","BK4207","LU1363072403.SGD","LU2361044865.SGD","IE00B7SZLL34.SGD","LU0942090050.USD","BK4585","LU0029864427.USD","LU0154236417.USD","LU0251142724.SGD","LU1074936037.SGD","LU1035773651.USD","LU0048573561.USD","LU1814569148.SGD","LU1069347547.HKD","BK4504","LU1267930573.SGD","LU0211327993.USD","BK4139","BK4588","LU0310799852.SGD","LU2236285917.USD","IE0002270589.USD","LU1668664300.SGD","LU0683600562.USD","LU0417517546.SGD","BK4096","LU0130102774.USD","LU1267930227.SGD","TLX.AU","LU0971096721.USD","KMX","TLX","LU0149725797.USD","LU1894683348.USD","LU0314106906.USD","LU0208291251.USD","LU0175139822.USD","TE","LU0251131958.USD","BK4559","LU0787776722.HKD","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":199,"code":"91000000","status":"200"}]}}